Application of Whole-Exome Sequencing to Unravel the Molecular Basis of Undiagnosed Syndromic Congenital Neutropenia with Intellectual Disability

Affiliation auteurs!!!! Error affiliation !!!!
TitreApplication of Whole-Exome Sequencing to Unravel the Molecular Basis of Undiagnosed Syndromic Congenital Neutropenia with Intellectual Disability
Type de publicationJournal Article
Year of Publication2017
AuteursGauthier-Vasserot A, Thauvin-Robinet C, Bruel A-L, Duffourd Y, St-Onge J, Jouan T, Riviere J-B, Heron D, Donadieu J, Bellanne-Chantelot C, Briandet C, Huet F, Kuentz P, Lehalle D, Duplomb-Jego L, Gautier E, Maystadt I, Pinson L, Amram D, Chehadeh SEl, Melki J, Julia S, Faivre L, Thevenon J
JournalAMERICAN JOURNAL OF MEDICAL GENETICS PART A
Volume173
Pagination62-71
Date PublishedJAN
Type of ArticleArticle
ISSN1552-4825
Mots-clésintellectual disability, syndromic congenital neutropenia, whole-exome sequencing
Résumé

Neutropenia can be qualified as congenital when of neonatal onset or when associated with extra-hematopoietic manifestations. Overall, 30% of patients with congenital neutropenia (CN) remain without a molecular diagnosis after a multidisciplinary consultation and tedious diagnostic strategy. In the rare situations when neutropenia is identified and associated with intellectual disability (ID), there are few diagnostic hypotheses to test. This retrospective multicenter study reports on a clinically heterogeneous cohort of 10 unrelated patients with CN associated with ID and nomolecular diagnosis prior to whole-exome sequencing (WES). WES provided a diagnostic yield of 40%(4/10). The results suggested that in many cases neutropenia and syndromic manifestations could not be assigned to the same molecular alteration. Three sub-groups of patients were highlighted: (i) severe, symptomatic chronic neutropenia, detected early in life, and related to a known mutation in the CN spectrum (ELANE); (ii) mild to moderate benign intermittent neutropenia, detected later, and associated with mutations in genes implicated in neurodevelopmental disorders (CHD2, HUWE1); and (iii) moderate to severe intermittent neutropenia as a probably undiagnosed feature of a newly reported syndrome (KAT6A). Unlike KAT6A, which seems to be associated with a syndromic form of CN, the other reported mutations may not explain the entire clinical picture. Although targeted gene equencing can be discussed for the primary diagnosis of severe CN, we suggest that performing WES for the diagnosis of disorders associating CN with ID will not only provide the etiological diagnosis but will also pave the way towards personalized care and follow-up. (C) 2016 Wiley Periodicals, Inc.

DOI10.1002/ajmg.a.37969